Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price dropped 7.7% on Tuesday . The stock traded as low as C$0.36 and last traded at C$0.36. Approximately 239,867 shares traded hands during mid-day trading, an increase of 16% from the average daily volume of 206,496 shares. The stock had previously closed at C$0.39.
Theralase Technologies Stock Performance
The company has a debt-to-equity ratio of 29.26, a current ratio of 0.83 and a quick ratio of 3.40. The firm has a market cap of C$86.12 million, a price-to-earnings ratio of -17.78 and a beta of -0.31. The company has a fifty day moving average price of C$0.29 and a two-hundred day moving average price of C$0.24.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Articles
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
